CDKN2A and acute lymphoblastic leukemia: This is line with the recent observation that IKF1-mutated Ph-positive high-risk ALL, in which IKF1 and Arf alterations synergistically promote the development of an aggressive lymphoid leukemia, can be effectively treated with retinoid receptor agonists which potentiate the activity of dasatinib in mouse and human BCR-ABL1 ALL [43].